PDSB News and Press, PDS Biotechnology Corporation From 06/02/22

FLORHAM PARK, N.J., June 02, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of molecularly targeted cancer immunotherapies and infectious disease vaccines based on the Company’s proprietary Vers...

PDS Biotechnology (NASDAQ:PDSB) said that the U.K.'s Medicines and Healthcare products Regulatory Agency (MHRA) accepted its clinical trial application (CTA) to start a study, called VERSATILE-002, of PDS0101 in combination with Merck's (MRK) Keytruda (pembrolizumab). The compa...

FLORHAM PARK, N.J., May 31, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of molecularly targeted cancer immunotherapies and infectious disease vaccines based on the Company’s propri...

Phase 2 Triple Combination Study Data To Be Presented At ASCO. PDS Biotech will be making two data presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting, scheduled for June 3-7. A poster presentation of preliminary data from the Phase 2 Triple Combination trial is sc...

Phase 2 VERSATILE Study Data To Be Presented. PDS Biotech will be making two data presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting, scheduled for June 3-7. A poster presentation of preliminary data from the Phase 2 VERSATILE-002 clinical trial is scheduled for J...

Positive results were announced from the phase 2 NCI-led PDS0101 triple-combination study in patients with HPV16+ cancers; both CPI naive and CPI refractory patients were helped. Positive results were also announced from the phase 2 study using PDS0101 + Keytruda for recurrent or meta...

PDS Biotechnology (NASDAQ:PDSB) reported data from an ongoing phase 2 trial of PDS0101 in combination with M9241 and bintrafusp alfa in certain cancers. The triple combination is being evaluated in patients with advanced HPV-positive anal, cervical, head and neck, vaginal, and vulvar can...

Preliminary data from first 19 patients treated with PDS0101 in combination with KEYTRUDA ® (pembrolizumab) demonstrates 41% response rate thus far for first line recurrent or metastatic head and neck cancer, in comparison to the published results of approximately 19% for...

77% of checkpoint inhibitor (CPI) refractory patients alive at median follow up of 12 months 75% of CPI naïve patients alive at median follow up of 17 months Anti-tumor objective responses seen in 88% of CPI naïve patients and 63% CPI refractory patients (high do...

FLORHAM PARK, N.J., May 25, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of molecularly targeted cancer immunotherapies and infectious disease vaccines, today announced its management team will ho...